TuHURA Biosciences Gains Orphan Drug Designation for Cutting-Edge Melanoma Treatment TuHURA Biosciences has received FDA Orphan Drug Designation for IFx-2.0, a promising treatment for advanced cutaneous melanoma. This offers hope for many patients.

TuHURA Biosciences Gains Orphan Drug Designation for Cutting-Edge Melanoma Treatment #USA #FDA #Tampa #TuHURA #IFx-2.0

TuHURA Biosciences Initiates $15.6 Million Fundraising Through Registered Direct Offering TuHURA Biosciences has launched a registered direct offering worth $15.6 million to further its cancer immunotherapy advancements, targeting significant funding for its innovative projects.

TuHURA Biosciences Initiates $15.6 Million Fundraising Through Registered Direct Offering #USA #Tampa #Cancer_Immunotherapy #TuHURA #IFx-2.0

FDA Lifts Clinical Hold on TuHURA Biosciences’ IFx-2.0 Trial for Merkel Cell Carcinoma Advancement TuHURA Biosciences secures approval to commence its Phase 3 trial for IFx-2.0 against Merkel Cell Carcinoma post FDA clinical hold lift.

FDA Lifts Clinical Hold on TuHURA Biosciences’ IFx-2.0 Trial for Merkel Cell Carcinoma Advancement #USA #Tampa #TuHURA #Merkel_Cell_Carcinoma #IFx-2.0

Breaking New Ground in Melanoma Treatment: TuHURA and Kineta's Latest Findings Discover the latest results from TuHURA Biosciences and Kineta regarding advanced melanoma treatment from their Phase I-II study presented at AACR.

Breaking New Ground in Melanoma Treatment: TuHURA and Kineta's Latest Findings #United_States #Chicago #TuHURA #Kineta #KVA12123

Monteverde & Associates Investigates Kineta, Inc.'s Proposed Merger with TuHURA Biosciences Monteverde & Associates PC is probing Kineta, Inc.'s merger with TuHURA Biosciences, focusing on shareholder safety and rights. Find out more!

Monteverde & Associates Investigates Kineta, Inc.'s Proposed Merger with TuHURA Biosciences #USA #New_York #Monteverde #TuHURA #Kineta

Investigating the TuHURA Biosciences Merger: A Class Action Overview Monteverde & Associates PC is looking into the merger of TuHURA Biosciences and Kineta, focusing on shareholder rights and investments.

Investigating the TuHURA Biosciences Merger: A Class Action Overview #United_States #New_York #Monteverde #TuHURA #Kineta

Not sure why the jaw bone is on the butt! Don’t let entomologists have a go at vertebrate anatomy @OtagoMuseum #Tuhura

Never let an entomologist do the vertebrate anatomy! @nzhymenoptera @OtagoMuseum #Tuhura

Cool way to learn about topography @OtagoMuseum #tuhura

So cool! @nzhymenoptera making stop-motion animation @OtagoMuseum #Tuhura science centre